About ReproCELL Europe

ReproCELL Europe Ltd, a new company formed on 1st July 2016, is a combination of two companies acquired by ReproCELL in recent years – Reinnervate and Biopta.

ReproCELL Europe offers the full range of translational research products and services of the ReproCELL Group to Europe, Middle East and Africa (EMEA). Through our ongoing research and development synergy we are bringing to market unique and competitive products and services to accelerate research in stem cells, human tissues and 3D cell culture.

ReproCELL Europe – History

Reinnervate: Reinnervate was founded in 2002 by Professor Stefan Przyborski as a spinout biotechnology company from Durham University, UK. Reinnervate was aquired by ReproCELL in 2014 and was merged with Biopta to form ReproCELL Europe Ltd in July 2016.

Reinnervate’s core strength was in its Alvetex® family of 3D cell culture products, providing a flexible platform that allows scientists in any life science laboratory to easily establish improved in vitro assays and tissue models that better mimic the in vivo growth of cells. Alvetex continues to be developed, produced and distributed by ReproCELL Europe.

Biopta: With laboratories in Glasgow, UK, and Maryland, USA, Biopta has been providing contract research services to the pharmaceutical industry since 2002 and has established itself as the world leader in the use of fresh functional human tissues to better predict drug activity prior to clinical trials. Biopta was acquired by ReproCELL in 2015 and was merged with Reinnervate to form ReproCELL Europe Ltd in July 2016.

Biopta’s expertise in all areas of human tissues research including sourcing, handling and experimenting on human tissue allows us to act as your “Human Tissue Research Department”. Now as part of ReproCELL Europe, their expert scientists continue to be on-hand 24/7 to create data in fresh human tissues that will add commercial value and de-risk drug development programmes by predicting the safety, efficacy, absorption or metabolism of compounds in phenotypically-relevant healthy and diseased human tissues.

ReproCELL Europe continues to provide Reinnervate’s and Biopta’s products and services, together with all the products and services of entire ReproCELL group of companies.


ReproCELL Europe – Board of Directors

Dr Chikafumi Yokoyama, Chairman

Dr. Yokoyama joined ReproCELL Inc. in 2004 as a general manager of the business development division and became Chief Executive Officer in 2005. He has been responsible for new product management, alliance, and fund raising. He also participated in establishing a Stem Cell and Drug Discovery Institute in which human ES cell research is carried out for the purpose of drug discovery and toxicity testing applications. From 1996 to 2004, Dr Yokoyama worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, as an R&D leader. He received his Ph.D. in chemistry from Tokyo University in 1996.

Dr David Bunton, CEO

David, an experienced and respected human tissue pharmacologist, was one of the co-founders of Biopta Ltd. Prior to forming Biopta, David was a Lecturer in Physiology and Pharmacology at Glasgow Caledonian University and remains a regular contributor to the field of human tissue research. David is a member of the British Pharmacological Society and Safety Pharmacology Society and is also active in promoting greater access to human tissues for medical research in the UK and USA.

Prof Stefan Przyborski, CSO

Professor Stefan Przyborski was the scientific founder of Reinnervate Ltd has been part of the ReproCELL group since since it’s acquisition in 2014. He also holds an academic position in the School of Biological and Biomedical Science at Durham University as Professor of Cell Technology. He has over 25 years of research experience within the fields of cell and tissue biology with specialization in stem cell science, cell differentiation and the development of advanced technologies that enable the construction of human tissues in vitro. Professor Przyborski runs an active research laboratory consisting of postdoctoral and postgraduate researchers. His group is well funded and regularly publishes their work in peer reviewed journals.

Daisuke Usui, CCO

Since 2003 Daisuke Usui has been leading numerous business units and companies in healthcare across both mature and emerging markets globally, and he has successfully brought significant leadership and sustainable growth. He has an unique portfolio and diverse experience within sales and marketing, supply chain, strategy development, finance and HR. Daisuke joined the ReproCELL group in September 2015.


About our parent company, ReproCELL Inc

Integrated Tools for Translational Research

ReproCELL is a global provider of embryonic and induced pluripotent stem cell reagents, and iPS cell-derived differentiated cell types.

The ReproCELL Group product range encompasses embryonic and induced pluripotent stem cells (ES/iPS), stem cell-derived functional cell types and associated reagents, a biorepository of human tissue samples, drug development services focusing on the development and application of assays using fresh and functional human tissues, and systems for 3D cell culture and tissue constructs.

ReproCELL Inc. was established in 2003 with the goal of contributing to people’s health and welfare through the development of stem cell technologies. Many of ReproCELL’s original technologies were developed by stem cell pioneers, Prof. Norio Nakatsuji from the Institute for Integrated Cell-Material Sciences, Kyoto University, and Prof. Hiromitsu Nakauchi from The Institute of Medical Sciences, The University of Tokyo.

Read more about ReproCELL Inc (on the ReproCELL website)